Cargando…
E-site drug specificity of the human pathogen Candida albicans ribosome
Candida albicans is a widespread commensal fungus with substantial pathogenic potential and steadily increasing resistance to current antifungal drugs. It is known to be resistant to cycloheximide (CHX) that binds to the E–transfer RNA binding site of the ribosome. Because of lack of structural info...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132455/ https://www.ncbi.nlm.nih.gov/pubmed/35613268 http://dx.doi.org/10.1126/sciadv.abn1062 |
_version_ | 1784713382439419904 |
---|---|
author | Zgadzay, Yury Kolosova, Olga Stetsenko, Artem Wu, Cheng Bruchlen, David Usachev, Konstantin Validov, Shamil Jenner, Lasse Rogachev, Andrey Yusupova, Gulnara Sachs, Matthew S. Guskov, Albert Yusupov, Marat |
author_facet | Zgadzay, Yury Kolosova, Olga Stetsenko, Artem Wu, Cheng Bruchlen, David Usachev, Konstantin Validov, Shamil Jenner, Lasse Rogachev, Andrey Yusupova, Gulnara Sachs, Matthew S. Guskov, Albert Yusupov, Marat |
author_sort | Zgadzay, Yury |
collection | PubMed |
description | Candida albicans is a widespread commensal fungus with substantial pathogenic potential and steadily increasing resistance to current antifungal drugs. It is known to be resistant to cycloheximide (CHX) that binds to the E–transfer RNA binding site of the ribosome. Because of lack of structural information, it is neither possible to understand the nature of the resistance nor to develop novel inhibitors. To overcome this issue, we determined the structure of the vacant C. albicans 80S ribosome at 2.3 angstroms and its complexes with bound inhibitors at resolutions better than 2.9 angstroms using cryo–electron microscopy. Our structures reveal how a change in a conserved amino acid in ribosomal protein eL42 explains CHX resistance in C. albicans and forms a basis for further antifungal drug development. |
format | Online Article Text |
id | pubmed-9132455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-91324552022-06-01 E-site drug specificity of the human pathogen Candida albicans ribosome Zgadzay, Yury Kolosova, Olga Stetsenko, Artem Wu, Cheng Bruchlen, David Usachev, Konstantin Validov, Shamil Jenner, Lasse Rogachev, Andrey Yusupova, Gulnara Sachs, Matthew S. Guskov, Albert Yusupov, Marat Sci Adv Biomedicine and Life Sciences Candida albicans is a widespread commensal fungus with substantial pathogenic potential and steadily increasing resistance to current antifungal drugs. It is known to be resistant to cycloheximide (CHX) that binds to the E–transfer RNA binding site of the ribosome. Because of lack of structural information, it is neither possible to understand the nature of the resistance nor to develop novel inhibitors. To overcome this issue, we determined the structure of the vacant C. albicans 80S ribosome at 2.3 angstroms and its complexes with bound inhibitors at resolutions better than 2.9 angstroms using cryo–electron microscopy. Our structures reveal how a change in a conserved amino acid in ribosomal protein eL42 explains CHX resistance in C. albicans and forms a basis for further antifungal drug development. American Association for the Advancement of Science 2022-05-25 /pmc/articles/PMC9132455/ /pubmed/35613268 http://dx.doi.org/10.1126/sciadv.abn1062 Text en Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited. |
spellingShingle | Biomedicine and Life Sciences Zgadzay, Yury Kolosova, Olga Stetsenko, Artem Wu, Cheng Bruchlen, David Usachev, Konstantin Validov, Shamil Jenner, Lasse Rogachev, Andrey Yusupova, Gulnara Sachs, Matthew S. Guskov, Albert Yusupov, Marat E-site drug specificity of the human pathogen Candida albicans ribosome |
title | E-site drug specificity of the human pathogen Candida albicans ribosome |
title_full | E-site drug specificity of the human pathogen Candida albicans ribosome |
title_fullStr | E-site drug specificity of the human pathogen Candida albicans ribosome |
title_full_unstemmed | E-site drug specificity of the human pathogen Candida albicans ribosome |
title_short | E-site drug specificity of the human pathogen Candida albicans ribosome |
title_sort | e-site drug specificity of the human pathogen candida albicans ribosome |
topic | Biomedicine and Life Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132455/ https://www.ncbi.nlm.nih.gov/pubmed/35613268 http://dx.doi.org/10.1126/sciadv.abn1062 |
work_keys_str_mv | AT zgadzayyury esitedrugspecificityofthehumanpathogencandidaalbicansribosome AT kolosovaolga esitedrugspecificityofthehumanpathogencandidaalbicansribosome AT stetsenkoartem esitedrugspecificityofthehumanpathogencandidaalbicansribosome AT wucheng esitedrugspecificityofthehumanpathogencandidaalbicansribosome AT bruchlendavid esitedrugspecificityofthehumanpathogencandidaalbicansribosome AT usachevkonstantin esitedrugspecificityofthehumanpathogencandidaalbicansribosome AT validovshamil esitedrugspecificityofthehumanpathogencandidaalbicansribosome AT jennerlasse esitedrugspecificityofthehumanpathogencandidaalbicansribosome AT rogachevandrey esitedrugspecificityofthehumanpathogencandidaalbicansribosome AT yusupovagulnara esitedrugspecificityofthehumanpathogencandidaalbicansribosome AT sachsmatthews esitedrugspecificityofthehumanpathogencandidaalbicansribosome AT guskovalbert esitedrugspecificityofthehumanpathogencandidaalbicansribosome AT yusupovmarat esitedrugspecificityofthehumanpathogencandidaalbicansribosome |